MSX (ASX: MSX)
Health care · News and insights
Price unavailable
Latest MSX announcements
Announcement Insights
Miro Sciences Advances Preparations For Crohn’s Trial, Targeting Year-End Start
Miro Sciences has progressed preparations for a planned Phase 2 trial of its StemSmart therapy in treatment-resistant Crohn’s disease, most recently reporting completion of a TGA inspection of its manufacturing partner. After announcing the planned Australian and US trial in October and positive FDA feedback and a clinical research organisation appointment, the company is targeting initiation by the end of 2026, subject to regulatory approvals. It reported approximately $4 million in cash at September-end.
Updated 12 Nov 2026, 09:17 AM Sydney time
Sources
Manufacturing Milestone Achieved - TGA Inspection CompletedIntroducing Miro Sciences Ltd - PresentationName Change to Miro Sciences (MSX)Comments
2026-11-12 · Health care
MSX: $0.041 +0.00% · MC: $16M
Miro Sciences says the TGA has completed its inspection of manufacturing partner Q-Gen, a step towards supplying StemSmart for a planned Phase 2 trial in treatment-resistant Crohn’s disease, subject to regulatory approvals. The company is targeting trial initiation by the end of 2026, following positive FDA feedback and the appointment of a clinical research organisation in October.
Updated 2026-11-12 09:07
Sources
Manufacturing Milestone Achieved - TGA Inspection CompletedComments
2026-11-05 · Health care
MSX: $0.052 +15.56% · MC: $16M
Miro Sciences’ investor presentation positions its StemSmart cell therapy for patients with severe Crohn’s disease who have failed existing treatments, and says the company is preparing for a planned Phase 2 trial in Australia and the United States. The presentation reports approximately $4 million in cash at the end of September and a market capitalisation of approximately $20 million as of November.
Updated 2026-11-05 09:14
Sources
Introducing Miro Sciences Ltd - PresentationComments
2026-10-28 · Health care
MSX: $0.054 +0.00% · MC: $16M
The company’s name change to Miro Sciences Ltd and ticker change from NSB to MSX took effect after shareholder approval and formal registration. The company says the new identity reflects its focus on its StemSmart cell therapy platform and preparations for a planned phase 2 trial in Australia and the United States for potential treatments for refractory Crohn’s disease.
Updated 2026-10-28 10:27
Sources
Name Change to Miro Sciences (MSX)Comments
Comments